METHODS: 82 subjects were recruited in this case-control study. Treatment subjects (n = 41) received oral alendronic acid treatment for at least 1-year and were matched by gender and age (± 2) to control subjects (n = 41) not receiving any anti-osteoporotic medication. The prevalence, type, and extent of MCs were quantified upon T1 and T2-weighted MRIs of the lumbosacral spine.
RESULTS: Treatment subjects received oral alendronic acid for 124.0 ± 62.1 weeks at the time of MRI assessment and exhibited a lower prevalence of MCs over the lumbosacral spine (18/41 vs. 30/41, p < 0.001) as compared to control subjects. Amongst both groups, type 2 MCs were predominant. Quantification of type 2 MCs in treatment subjects revealed a significant reduction in area (113 ± 106 mm2 vs. 231 ± 144 mm2, p < 0.01) and volume (453 ± 427 mm3 vs. 925 ± 575 mm3, p < 0.01) affected by type 2 MCs in comparison to matched controls.
CONCLUSIONS: Oral alendronic acid may be useful in the treatment of MC-associated LBP in patients with concomitant osteoporosis.
方法:本病例对照研究招募了82名受试者。治疗受试者(n=41)接受口服阿仑膦酸治疗至少1年,性别和年龄(±2)与未接受任何抗骨质疏松药物的对照受试者(n=41)相匹配。患病率,type,根据T1和T2加权MRI对MC的范围进行量化。
结果:治疗对象在MRI评估时口服阿仑膦酸124.0±62.1周,并且表现出腰骶椎MC的患病率较低(18/41vs.30/41,p<0.001)与对照受试者相比。在两组中,以2型MC为主。治疗对象中2型MC的定量显示面积显着减少(113±106mm2与231±144mm2,p<0.01)和体积(453±427mm3与925±575mm3,p<0.01)与匹配的对照相比受2型MC的影响。
结论:口服阿仑膦酸可用于合并骨质疏松症患者MC相关LBP的治疗。